Organized by ReSViNET 4th RESVINET CONFERENCE ON RSV THERAPEUTICS

RSVVW ‘17

RSV VACCINES FOR THE WORLD

November 29th – December 1st 2017Málaga, Spain

ORGANIZING COMMITTEE

Chair – Janet EnglundChildren's Hospital & Medical Center, Seattle, United States

Chair – Asuncion Mejias The Research Institute At Nationwide Children's Hospital, Columbus, Ohio, United States

Leyla Kragten-TabatabaieJulius Clinical, Zeist & University Medical Center Utrecht, Utrecht, The Netherlands

Louis BontWilhelmina Children’s Hospital University Medical Center Utrecht, Utrecht, The Netherlands

Tessa KliestJulius Clinical, Zeist, The Netherlands

Natalie MazurWilhelmina Children’s Hospital University Medical Center Utrecht, Utrecht, The Netherlands

SCIENTIFIC ADVISORY COMMITTEERuth KarronJohns Hopkins Bloomberg School of Public Health, Baltimore, United States

Louis BontWilhelmina Children’s Hospital University Medical Center Utrecht, Utrecht, The Netherlands

Helen ChuUniversity Of Washington, Washington, United States

Janet EnglundChildren's Hospital & Medical Center, Seattle, United States

Ann FalseyUniversity Of Rochester Medical Center, New York, United States

Barney GrahamViral Pathogensis Laboratory And Translational Science Core & National Institute Of Allergy And Infectious Diseases, Bethesda, United States

Deborah HigginsRSV Vaccine Project at Path, Seattle, Washington, United States

Leyla Kragten-TabatabaieJulius Clinical, Zeist & University Medical Center Utrecht, Utrecht, The Netherlands

Asuncion Mejias The Research Institute At Nationwide Children's Hospital, Columbus, Ohio, United States

Harish NairUsher Institute Of Population Health Sciences &Informatics & The University Of Edinburgh Medical School, Edinburgh, United Kingdom

Marta NunesUniversity Of Witwatersrand, Johannesburg, South Africa & Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa

Peter OpenshawFaculty Of Medicine, National Heart & Lung Institute, Imperical College London, London, United Kingdom

Pedro A. PiedraBaylor College Of Medicine, Texas, United States

PROGRAM | DAY 1 WEDNESDAY 29 NOVEMBER

11:00 – 15.00 ReSViNET Board Meeting

12:00 Registration and badge retrieval

16:00 – 16:15

16:15 – 16:45

Welcome and opening by Asuncion Mejias & Janet Englund

Keynote Lecture: RSV F structural biology for beginners: antigenic sites and epitopes

(Jason McLellan)

Session I RSV BURDEN AND INFANT MORTALITY

16:45 – 17:00

17:00 – 17:30

17:30 – 18:00

18:00 – 18:30

Session introduction, identifying gaps and aims of session (Chair: Fernando

Polack/Vasee Moorthy)

RSV Burden: Global mortality (Harish Nair)

The burden of RSV community mortality and how to tackle it (Fernando Polack)

General round table discussion

18:30 – 19:30 YOUNG RESEARCHERS TOURNAMENT

(4 selected short presentations by young researchers)

20:00 Welcome Drinks and Tapas

Session II VIRUS STRUCTURE AND VACCINE DESIGN

08:30 – 08:45

08:45 – 09:15

09:15 – 09:45

09:45 – 10:15

10:15 – 10:45

Session introduction, identifying gaps and aims of session (Chair: Barney Graham/Ruth

Karron)

Viral Fusion Proteins: Structure-Guided Vaccine Antigen Design (Barney Graham)

Progress in the Development of Live Attenuated RSV Vaccines (Ruth Karron)

Accelerating vaccine development global program (Deborah Higgins)

Interactive round table discussion with the speakers

10:45 – 11:30 Coffee/Tea break & Posters

Session III RSV ANTIBODIES, ARE THEY THE MAIN SURROGATE OF PROTECTION?

11:30 – 11:45

11:45 – 12:15

12:15 – 12:45

12:45 – 13:15

13:15 – 13:30

Session introduction, identifying gaps and aims of session (Chair: Helen Chu/Pedro

Piedra)

Transplacental antibody transfer, does time matters? (Helen Chu)

Is it pre F, post F or G? (Jose Melero)

What is the threshold of protection? (Pedro Piedra)

Interactive round table discussion with the speakers

13:30 – 14:30 Lunch

Session IV RSV IN VULNERABLE POPULATIONS

14:30 – 14:45

14:45 – 15:05

15:05 – 15:25

15:25 – 15:45

15:45 – 16:00

Session introduction, identifying gaps and aims of session (Chair: Janet

Englund/Octavio Ramilo)

RSV burden in preterm infants (Anne Greenough)

RSV in immunocompromised patients (Jan Englund)

Human volunteer challenge and RSV vaccines for adults: what role could there be?

(Peter Openshaw)

Interactive round table discussion with the speakers

16:00 – 16:45 Coffee/Tea break & Posters

Session V RSV SURVEILLANCE AND GUIDELINES

16:45 – 16:50

16:50 – 17:10

17:10 – 17:30

17:30 – 17:50

17:50 – 18:10

18:10 – 18:30

18:30 – 18:45

18:45 – 19:45

Session introduction, identifying gaps and aims of session (Chair: Asuncion Meijas)

WHO Surveillance and efforts on RSV vaccine development (Joachim Hombach, WHO)

Guideline on the clinical evaluation of medicinal products indicated for the prophylaxis

or treatment of RSV disease (Mair Powell, EMA)

Viewpoint FDA on RSV prevention (TBA)

RSV surveillance in the United States (Susan Gerber, CDC)

RSV Vaccines for antimicrobial resistance (Keith Klugman, Bill & Melinda Gates

Foundation)

Interactive round table discussion with the speakers

YOUNG RESEARCHERS EXPERT WORKSHOP (only for young researchers to attend)

20:00 – 23:00 Dinner

PROGRAM | DAY 2 THURSDAY 30 NOVEMBER

PROGRAM | DAY 3 FRIDAY 1 DECEMBER

Session VI STATUS OF VACCINE DEVELOPMENTS

08:30 – 08:35

08:35 – 09:00

09:00 – 09:15

09:15 – 09:30

09:30 – 09:45

09:45 – 10:00

10:00 – 10:15

10:15 – 10:30

10:15 – 10:45

Session introduction, identifying gaps and aims of session (Chair: Ann Falsey/Keith

Klugman)

History and future of RSV vaccines (Ed Walsh)

Presenter to be selected 1*

Presenter to be selected 2

Presenter to be selected 3

Presenter to be selected 4

Presenter to be selected 5

Presenter to be selected 6

Interactive round table discussion with the speakers

*All Presenters to be selected involved in RSV manufactory will be invited to send an abstract which will be

reviewed and evaluated by the organizing committee. Based on the scientific content and value 6 will be selected

to speak at the venue.

10:45 – 11:30 Coffee/Tea break & Posters

Session VII SURROGATE MARKERS OF VACCINE EFFICACY: SEROLOGY AND BEYOND

11:30 – 11:35

11:35 – 12:05

12:05 – 12:35

12:35 – 13:05

13:05 – 13:30

Session introduction, identifying gaps and aims of session (Chair: Peter Openshaw

/Marta Nunes)

Predictors to immune responses to vaccination in young infants (Octavio Ramilo)

Clinical endpoints in trials of RSV vaccines in pregnant women: study design issues,

assessment of safety and effectiveness (Marta Nunes)

Immune response to vaccines in the elderly (Ann Falsey)

Round Table Discussion with the speakers

13:30 – 14:30 Lunch

Session VIII RSV AND LONG-TERM SEQUELAE

14:30 – 14:40

14:40 – 15:10

15:10 – 15:40

15:40 – 16:10

16:10 – 16:30

16:30 – 16:40

16:40 – 17:00

Session introduction, identifying gaps and aims of session (Chair: Louis Bont /Renato

Stein)

The epidemiological link between RSV and asthma (Tina Hartert)

Lessons learned from Immunoprophylaxis RCTs (Eric Simoes)

Follow-up in RSV Vaccine Trials: how long is enough? (Louis Bont)

Interactive round table discussion with the speakers

Announcement Winner Young Researchers Tournament (Natalie Mazur/Leyla Kragten)

Closing Remarks Asuncion Mejias and Louis Bont

LOCATION

The conference will take place in theSpanish city Málaga.

Málaga is a city on the Mediterranean inSouth Spain and the heart of the Costa delSol. The vibrant cosmopolitan city of Málagais situated on the beautiful Andalucíacoastline. Blessed with sunshine, Málagaprovides lively nightlife, museums andexceptional seafood restaurants alongsidewide boulevards, swaying palm trees andbeautiful beaches.

Guests can enjoy the beautiful and quietseaside, visit the Picasso museum andPicasso’s birth house, walk through thesmall and picturesque streets in the historiccentre and have the possibility to encounterAntonio Banderas, who is the pride of thecity.

LOCATION & ACCOMODATION

RSV Vaccines for the World 2017 will be heldin the heart of the Spanish city Málaga, inCine Albéniz.

Cine Albéniz is an old characteristic cinemawhich is located in the historic centre ofMálaga next to the roman theatre whichwas built in the 1st century AD and theAlcabaza castle which was built in order toprotect the city from its enemies.

We would like to recommend the AC Hotel Malaga Palacio. From the conference center it takes 3 minutes by foot to arrive at AC Hotel Malaga Palacio. The hotel is located in the center of a shopping area, in the vicinity of Museo Automovilistico De Malaga, Museum of Malaga and Malagueta Beach.

RSVVW ‘17 does not have an arrangement with AC Hotel Malaga Palacio, bookings can be made through their website.

Address: Address:AC Malaga Palacio Hotel Cine AlbénizCortina Del Muelle, 1 Alcazabilla, 429015, Malaga, 29015, MálagaSpain Spain

PARTICIPANT REGULAR FEE(PAYMENT RECEIVED BY 31 OCT.)

LATE FEE(PAYMENT RECEIVED AFTER 1ST OF NOV.)

BENEFITS LINKED TO THE REGISTRATION FEE

Full Participants € 750 € 880 • Attendance to all scientific sessions• Poster sessions• Invitation to the Opening Reception• Refreshments during the meeting and

lunch • Dinner and networking on 30th of

November • Congress material

(PhD) Students, Fellows and Trainees

€ 295 € 365 • Attendance to all scientific sessions • Poster sessions• Activities young researchers

(presentation tournament &masterclass)

• Invitation to the Opening Reception• Refreshments during the meeting and

lunch • Dinner and networking on 30th of

November • Congress material

REGISTRATION & FEES

TRAVEL AWARDS

ReSViNET is committed to contribute to support, based on quality, developing countryparticipants and young researchers.

TRAVEL FELLOWSHIP AWARD POLICY AND REQUIREMENTS Bursaries will be available for young researchers such as PhD students, post-docs, medical

residents or certified specialists (with no more than 3 years practice), judged on the quality ofabstracts.

EU awardees will receive €1000, non-EU awardees will receive €2000 as a lump sum for allexpenses.

Priority will be given to applicants from an economically disadvantaged area. Click Here toview the list. However, applicants from all countries are welcome to submit.

Applicants must currently work or study in the field of respiratory infectious diseases, andmust provide documentation on their institution’s letterhead with a letter from thedepartment head confirming their current position.

One application per registrant.

The master class is exclusively for young researchers such as PhD students, post-docs, medical residents or certified specialists (with no more than 3 years practice), given by an expert in the field of RSV. The focus of the master class will address an overarching theme in medical research. Attendance will be through an application process as there are limited spaces available.

MASTER CLASS

Send all documentation to info@resvinet.org

SUBMISSION DEADLINE SEPTEMBER 1, 2017

MORE INFORMATION WILL FOLLOW SOON

ABSTRACT SUBMISSION GUIDELINES

Abstract Submission Starts June, 2017

Abstract Submission Deadline Friday, September 1, 2017

Notification of Selected Abstracts Friday, September 29, 2017

Registration Deadline for Selected Presenters Wednesday, October 25, 2017

ABSTRACT SUBMISSION GUIDELINESPlease follow the instructions listed below:

Abstracts can be submitted to info@resvinet.org. The email subject must clearly state:ABSTRACT SUBMISSION RSV VACCINES FOR THE WORLD MEETING 2017.

Abstracts must be received by the announced deadline. Abstracts received after thedeadline will not be considered.

Submission of an abstract acknowledges the acceptance for the abstract to be published inthe official meeting publications.

Presenting authors must be registered participants in order to be scheduled for postersessions and presentation.

Abstracts must be submitted in English. Abstracts over 250 words will not be accepted. Please indicate if you wish to participate in the Young Researchers Tournament.

The Scientific Committee will review and determine whether the abstract will be accepted as aposter presentation or participation in the Young Researchers Tournament, with considerationgiven to the author's preference.

The presenting author is assumed to have approval from all co-authors to submit the abstract.

ABSTRACT PREPARATIONBefore you begin, please prepare the following information: Contact details presenting author

Email address Full postal address Daytime and evening phone number

Details (co)author(s) Full first and family name(s) (upper and lowercase for example John C. Smith.) Affiliation details (department, institution/hospital, city, state (if relevant), country)

Abstract title - limited to 25 words in UPPER CASE Abstract text - limited to 250 words including acknowledgements

YOUNG RSV RESEARCHERS TOURNAMENT

PARTICIPATIONPhD students, post-docs, medical residents orcertified specialists (with no more than 3 yearspractice since completing training or PhD) areeligible to apply. Eligible candidates may indicatethat they wish to participate in the tournamentwhen submitting an abstract. Written confirmationfrom the head of a candidate’s department aboutresident or PhD status has to be provided andsubmitted to info@resvinet.org.

SELECTION OF CANDIDATESThe Organizing Committee will select 4 candidatesto participate in the tournament on the basis of theabstract content.

FINANCIAL SUPPORTThe conference registration fee will be waived forcandidates who are selected for the tournament.

PRESENTATIONEach candidate is allotted 10 minutes forpresentation of his or her research and 5 minutesto answer questions from the jury. Thepresentations will take place on the first evening ofthe conference, November 29, 2017.

JURYThe jury consists of members of the ReSViNETboard, RSV vaccines for the world organizingcommittee, and SAC members.

EVALUATIONCandidates will be judged on (1) the scientific valueof the work presented, (2) the quality of the oralpresentation, and (3) the quality of responses tothe jury.

PRIZEThe winner of the tournament will receive a prizeconsisting of free registration, accommodation aswell as a travel grant for the ReSViNET 5th meetingin 2019. The prize is not transferable and will notbe paid off in cash.

ACKNOWLEDGEMENTS

Platinum Supporters*

Gold Supporters*

Silver Supporters

*Limited availability

The Organising Committee and the Board of ReSViNET would like to express gratitude andacknowledge the following companies and institutes for their generous support of the RSVVaccines for the World conference 2017, organised by ReSViNET.

Bronze Supporters

ReSViNET

ReSViNET is an international network of clinician

scientists with an integrated, multidisciplinary and

translational research approach focused on RSV

infection. ReSViNET is stimulating and performing

research aiming to understand the burden of RSV

infection, to advocate for better care for patients

with RSV infection and to provide effective

partnerships with relevant stakeholders.

ReSViNET Annual Meetings are devoted

exclusively to RSV infection prevention and

treatment and is focusing on the scientific

developments and demands in RSV field.

We aim to bring together the scientific data and

expertise, connecting different stakeholders

involved in RSV research e.g. Scientists, policy

makers and Pharmaceutical companies and

stimulating discussions regarding the

opportunities for future international

collaboration and achievement in our field.

WHY JOIN US?

• CONTINUE FOCUSING ON DEVELOPING RSV THERAPIES AND VACCINES

•REACH ACADEMIC LEADERS AND TOP SCIENTISTS IN THE FIELD

•NETWORKING WHILE WORKING

• CUTTING-EDGESCIENTIFIC RESEARCH

•OPPORTUNITIES FOR FUTURE INTERNATIONAL COLLABORATION

We look forward in welcoming you to Málaga between November 29th to December 1st for the RSV Vaccines for the World conference organised by ReSViNET.

If you have any questions or require additional information, please contact:

Leyla Kragten-Tabatabaie, PhDReSViNET Scientific Network Managert +31 (0)6 11331391e leyla.kragten@resvinet.orge info@resvinet.org w www.resvinet.org

RESVINET SITES & PARTNERS